BusinessEmerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic SclerodermaBy Nasdaq OMXOct 20, 2017, 11:00 AM UTC
BusinessNew U.S. Patent Allowance Granted to AXIM® Biotechnologies, Inc. for Cannabinoid Ophthalmic Solutions for Glaucoma and Conjunctivitis TreatmentBy Nasdaq OMXOct 5, 2017, 1:00 PM UTC
BusinessEarth Science Tech, Inc. Announces Interview on PotStockRadio, Contacto with Hilda Rabilero, & Floride TVBy Nasdaq OMXOct 5, 2017, 12:25 PM UTC
BusinessOak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for TuberculosisBy Nasdaq OMXOct 3, 2017, 1:00 PM UTC
BusinessEmerald Health Pharmaceuticals’ Scientific Team Leads Cannabinoid Research Showing Potential to Impact Neurodegenerative DiseasesBy Nasdaq OMXSep 20, 2017, 11:00 AM UTC
BusinessMadrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial HypercholesterolemiaBy Nasdaq OMXSep 19, 2017, 11:30 AM UTC
BusinessEmerald Health Pharmaceuticals to Treat Life-Threatening Diseases with Novel Synthetic Cannabinoid-Derived MoleculesBy Nasdaq OMXSep 14, 2017, 1:00 PM UTC
BusinessCURE Pharmaceutical Launches New Academic Partnership Program Providing the Company’s Proprietary CureFilm™ for More Humane and Effective Animal ResearchBy Nasdaq OMXSep 6, 2017, 1:00 PM UTC
